Literature DB >> 21194362

Novel aspects of cellular action of dipeptidyl peptidase IV/CD26.

Siegfried Ansorge1, Karsten Nordhoff, Ute Bank, Anke Heimburg, Heiko Julius, Doreen Breyer, Anja Thielitz, Dirk Reinhold, Michael Täger.   

Abstract

The cellular dipeptidyl peptidase IV (DPIV, E.C.3.4.14.5, CD26) is a type II membrane peptidase with various physio-logical functions. Our main knowledge on DPIV comes from studies of soluble DPIV which plays a role in regulation of glucose homeostasis by inactivation of the incretins glucagon-like peptide-1 and glucose-dependent insulinotropic poly-peptide. It has been reported that membrane-bound DPIV plays a crucial role in the immune system and in other tissues and cells, but the knowledge on the action of cellular DPIV and its regulation is limited. In this study, we show particularly for immune cells that DPIV and not DP8 or DP9 is the most potent member of the DPIV family in regulating cellular immune functions. Moreover, we provide evidence that soluble and cellular DPIV differ in functions and hand-ling of substrates and inhibitors owing to the different accessibility of peptide substrates to the two access paths of DPIV. The different functions are based on the favored access path of the central pore of cellular DPIV and a special central pore binding site which assists substrate access to the active site of the enzyme. The newly discovered central pore binding site mediates an autosterical regulation of cellular DPIV and is its most crucial target site to regulate cellular functions such as growth and cytokine production. Neuropeptide Y (NPY) processing by cellular DPIV was found to be inhibited by ligands which interact with the central pore binding site. This finding suggests a crucial role of the immunosuppressive cytokine NPY in the function of DPIV in growth regulation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21194362     DOI: 10.1515/BC.2011.008

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  10 in total

Review 1.  Diabetes mellitus and the skin.

Authors:  E Makrantonaki; D Jiang; A M Hossini; G Nikolakis; M Wlaschek; K Scharffetter-Kochanek; C C Zouboulis
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

Review 2.  Clinical therapeutic strategies for early stage of diabetic kidney disease.

Authors:  Munehiro Kitada; Keizo Kanasaki; Daisuke Koya
Journal:  World J Diabetes       Date:  2014-06-15

3.  Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection.

Authors:  Jonas Söderholm; Jesper Waldenström; Galia Askarieh; Massimo Pilli; Pierre-Yves Bochud; Francesco Negro; Jean-Michel Pawlotsky; Stefan Zeuzem; Carlo Ferrari; Gunnar Norkrans; Rune Wejstål; Johan Westin; Avidan U Neumann; Bart L Haagmans; Magnus Lindh; Gabriele Missale; Kristoffer Hellstrand; Martin Lagging
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

4.  Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia.

Authors:  Peter Röhnert; Werner Schmidt; Patrick Emmerlich; Alexander Goihl; Sabine Wrenger; Ute Bank; Karsten Nordhoff; Michael Täger; Siegfried Ansorge; Dirk Reinhold; Frank Striggow
Journal:  J Neuroinflammation       Date:  2012-02-28       Impact factor: 8.322

Review 5.  The Role of Dipeptidyl Peptidase - 4 Inhibitors in Diabetic Kidney Disease.

Authors:  Usha Panchapakesan; Carol Pollock
Journal:  Front Immunol       Date:  2015-08-28       Impact factor: 7.561

6.  Plasma DPP4 activity is associated with no-reflow and major bleeding events in Chinese PCI-treated STEMI patients.

Authors:  Jing Wei Li; Yun Dai Chen; Wei Ren Chen; Jing Jing; Jie Liu; Yong Qiang Yang
Journal:  Sci Rep       Date:  2016-12-21       Impact factor: 4.379

7.  Delayed allogeneic skin graft rejection in CD26-deficient mice.

Authors:  Xiangli Zhao; Kai Zhang; Peter Daniel; Natali Wisbrun; Hendrik Fuchs; Hua Fan
Journal:  Cell Mol Immunol       Date:  2018-03-23       Impact factor: 11.530

Review 8.  New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors.

Authors:  Chenkai Cui; Xuefei Tian; Linting Wei; Yinhong Wang; Kexin Wang; Rongguo Fu
Journal:  Front Pharmacol       Date:  2022-09-12       Impact factor: 5.988

9.  Linagliptin Limits High Glucose Induced Conversion of Latent to Active TGFß through Interaction with CIM6PR and Limits Renal Tubulointerstitial Fibronectin.

Authors:  Muralikrishna Gangadharan Komala; Simon Gross; Amgad Zaky; Carol Pollock; Usha Panchapakesan
Journal:  PLoS One       Date:  2015-10-28       Impact factor: 3.240

10.  Dipeptidyl Peptidase-4 Is a Pro-Recovery Mediator During Acute Hepatotoxic Damage and Mirrors Severe Shifts in Kupffer Cells.

Authors:  Nádia Duarte; Inês Coelho; Denys Holovanchuk; Joana Inês Almeida; Carlos Penha-Gonçalves; Maria Paula Macedo
Journal:  Hepatol Commun       Date:  2018-09-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.